Status:

COMPLETED

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Post-stroke Spasticity of the Upper Limb

Lead Sponsor:

Merz Pharmaceuticals GmbH

Conditions:

Post-stroke Upper Limb Spasticity

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

IncobotulinumtoxinA (Xeomin) is a botulinum toxin type A preparation free from complexing proteins, i.e. free from proteins other than the active toxin. Injected into the muscle, incobotulinumtoxinA (...

Eligibility Criteria

Inclusion

  • Main
  • Female or male patients ≥ 18 years
  • ≥ 6 months since the last stroke, diagnosed by an appropriate health care professional (e.g., neurologist)
  • Focal spasticity with ≥ 2 points on the Ashworth Scale in the wrist flexors with clinical pattern Flexed Wrist
  • Focal spasticity with ≥ 2 points on the Ashworth Scale in the fingers flexors with clinical pattern Clenched Fist
  • For pre-treated patients only: source documentation of the most recent injection session with Botulinum Toxin and sufficient therapeutic response for Flexed Wrist and Clenched Fist
  • For pre-treated patients only: the most recent injection with Botulinum Toxin must have been maximal 50 Units BOTOX® or 200 Units Dysport® or 2000 Units Neurobloc® (type B preparation) per each of these flexors: carpi ulnaris, digitorum superficialis, digitorum profundus
  • For pre-treated patients only: the most recent injection with Botulinum Toxin must have been maximal 60 Units BOTOX® or 240 Units Dysport® or 2400 Units Neurobloc® (type B preparation) for flexor carpi radialis
  • Main

Exclusion

  • Spasticity of any other origin than stroke
  • Previous treatment with Botulinum Toxin of any serotype and for any body region within the 4 months prior to Screening (Visit 1, Day -7)
  • Planned concomitant treatment with Botulinum Toxin of any serotype and for any body region
  • Previous or planned treatment with phenol- or alcohol-injection in the target limb
  • Previous surgical treatment of spasticity in the target muscle(s)
  • Fixed contracture, defined as severe restriction of the range of joint movement on passive stretch
  • Severe atrophy of the target limb muscles

Key Trial Info

Start Date :

June 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2008

Estimated Enrollment :

148 Patients enrolled

Trial Details

Trial ID

NCT00432666

Start Date

June 1 2006

End Date

May 1 2008

Last Update

December 15 2010

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Czech Republic, Czechia

2

Hungary, Hungary

3

Poland, Poland